Testicular cancer trial: could a stronger chemo course slash relapse risk?
NCT ID NCT02341989
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This phase 3 trial tests whether one round of BEP chemotherapy works better than one round of carboplatin to stop stage I seminoma testicular cancer from coming back. About 348 men with high-risk features (tumor over 4 cm or invasion of the rete testis) are being studied. The goal is to see which treatment leads to fewer relapses and how they affect quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEMINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institutt for kreftforskning og molekylær medisin, St Olavs Hospital
Trondheim, Norway
-
St. Olavs University hospital HF
Trondheim, Norway
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bleomycin, etoposide, and cisplatin (BEP) or carboplatin
What this could lead to
If BEP works better, it could offer a more effective way to prevent testicular cancer from coming back after surgery.
What could go wrong
This is an early-stage comparison; BEP may cause more side effects than carboplatin, and the trial is not testing a cure—just reducing relapse risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.